Sanofi oral SERD failed: Only one ADC in the phase 3 tumor pipeline
- Aspirin: Study Finds Greater Benefits for These Colorectal Cancer Patients
- Cancer Can Occur Without Genetic Mutations?
- Statins Lower Blood Lipids: How Long is a Course?
- Warning: Smartwatch Blood Sugar Measurement Deemed Dangerous
- Mifepristone: A Safe and Effective Abortion Option Amidst Controversy
- Asbestos Detected in Buildings Damaged in Ukraine: Analyzed by Japanese Company
Sanofi oral SERD failed: Only one ADC in the phase 3 tumor pipeline
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
Sanofi oral SERD failed: Only one ADC in the phase 3 tumor pipeline.
On August 17, Sanofi announced that it will discontinue the global clinical development program for its investigational oral selective estrogen receptor degrader (SERD) amcenestrant.
The decision was based on the results of a pre-specified interim analysis of the Phase 3 AMERA-5 trial in patients with estrogen receptor positive (ER+)/human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer , comparing the efficacy of amcenestrant combined with palbociclib and letrozole combined with palbociclib.
The Independent Data Monitoring Committee (IDMC) found that the combination of amcenestrant and palbociclib did not meet the predetermined limit for continued use compared with the control group and recommended that the trial be discontinued.
Sanofi said all other studies on amcenestrant, including early-stage breast cancer (AMEERA-6), will be discontinued.
Previously, Sanofi had seen the program as a future “endocrine backbone therapy” for breast cancer.
Amcenestrant took a major hit in March, when Sanofi disclosed the failure of an often-delayed phase 2 trial investigating the drug as a monotherapy for ER-positive, HER2-negative breast cancer.
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
